Img header logo

GRI Standards Content Index

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

GRI Standards Content Index

Our website refers to the Global Reporting Initiative (GRI) Standards.The descriptions are shown in this comparative table.

General disclosures 2021
Disclosure Number Description References/Response
1. The organization and its reporting practices
2-1 Organizational details
  1. Company Profile
  1. Business Locations
2-2 Entities included in the organization’s sustainability reporting
  1. Business Locations
  1. Sustainability Report 2023 (P.2)
2-3 Reporting period, frequency and contact point
  1. Sustainability Report 2023 (P.2)
2-5 External assurance
  1. Independent Practitioner's Assurance
  1. SUSTAINABILITY DATA 2023
2. Activities and workers
2-6 Activities, value chain and other business relationships
  1. Business Activities
2-7 Employees
  1. ESG Data/Social Data (Employees information)
2-8 Workers who are not employees
  1. ESG Data/Social Data (Employees information)
3. Governance
2-9 Governance structure and composition
  1. Corporate Governance Structure
  1. Corporate Report 2023 (PP.89-92)
2-10 Nomination and selection of the highest governance body
  1. Corporate Governance Structure
  1. Corporate Report 2023 (PP.89-94)
2-11 Chair of the highest governance body
  1. Corporate Report 2023 (PP.92-94)
2-12 Role of the highest governance body in overseeing the management of impacts
  1. Corporate Governance Structure
  1. Sustainability Promotion Structure
  1. Information Disclosure Based on the TCFD Recommendation
2-13 Delegation of responsibility for managing impacts
  1. Sustainability Promotion Structure
  1. Information Disclosure Based on the TCFD Recommendation
  1. Initiatives to Strengthen Compliance System
2-14 Role of the highest governance body in sustainability reporting
  1. Sustainability Promotion Structure
  1. EHS Management
  1. Information Disclosure Based on the TCFD Recommendation
2-15 Conflicts of interest
  1. Corporate Report 2023 (P.97)
2-16 Communication of critical concerns
  1. Risk Management
  1. Corporate Governance Structure
2-17 Collective knowledge of the highest governance body
  1. Corporate Governance Structure
  1. Corporate Report 2023 (PP.93-94)
2-18 Evaluation of the performance of the highest governance body
  1. Corporate Report 2023 (PP.93-94)
2-19 Remuneration policies
  1. Corporate Report 2023 (PP.95-96)
2-20 Process to determine remuneration
  1. Corporate Report 2023 (PP.95-96)
4. Strategy, policies and practices
2-22 Statement on sustainable development strategy
  1. Corporate Report 2023 (PP.15-20)
  1. Top message
2-23 Policy commitments
  1. ONO Group Code of Conduct
  1. Ono Group Human Rights Global Policy
  1. Basic Policy for Procurement Activities
2-24 Embedding policy commitments
  1. Respect for Human Rights
  1. Supply Chain Management
  1. Initiatives to Strengthen Compliance System
  1. EHS Management
2-25 Processes to remediate negative impacts
  1. Initiatives to Strengthen Compliance System
  1. Risk Management
  1. Sustainability Promotion Structure
  1. ESG Data/Governance Data
  1. Contact
2-26 Mechanisms for seeking advice and raising concerns
  1. Initiatives to Strengthen Compliance System
  1. ESG Data/Governance Data
2-27 Compliance with laws and regulations
  1. Compliance
  1. ESG Data/Governance Data
2-28 Membership associations The Federation of Pharmaceutical Manufacturers’ Associations of JAPAN, Japan Pharmaceutical Manufacturers Association, KEIDANREN (Japan Business Federation), Kansai Pharmaceutical Industries Association, etc.
5. Stakeholder engagement
2-29 Approach to stakeholder engagement
  1. Stakeholder Engagement
2-30 Collective bargaining agreements
  1. ESG Data/Social Data
GRI3:Material Topics 2021
3-1 Process to determine material topics
  1. Steps in materiality analysis
3-2 List of material topics
  1. Material Issues and KPI
3-3 Management of material topics
  1. Material Issues and KPI
Economic topics
Disclosure Number Description References/Response
GRI 201: Economic Performance 2016
201-1 Direct economic value generated and distributed
  1. Financial Highlights
201-2 Financial implications and other risks and opportunities due to climate change
  1. Information Disclosure Based on the TCFD Recommendation
  1. Risk Management
GRI 203: Indirect Economic Impacts 2016
203-1 Infrastructure investments and services supported
  1. Efforts Made for Improving Access to Healthcare
  1. Social Contribution Activities
GRI 205: Anti-corruption 2016
205-2 Communication and training about anti-corruption policies and procedures
  1. Initiatives to Strengthen Compliance System
  1. ESG Data/Governance Data
205-3 Confirmed incidents of corruption and actions taken
  1. Compliance
  1. ESG Data/Governance Data
GRI 207: Tax 2019
207-1 Approach to tax
  1. Ono Pharmaceutical Global Tax Policy
207-2 Tax governance, control, and risk management
  1. Ono Pharmaceutical Global Tax Policy
207-3 Stakeholder engagement and management of concerns related to tax
  1. Ono Pharmaceutical Global Tax Policy
207-4 Country-by-country reporting
  1. Tax Reporting by Country
Environmental topics
Disclosure Number Description References/Response
GRI 302: Energy 2016
302-1 Energy consumption within the organization
  1. ESG Data/Environmental Data
302-2 Energy consumption outside of the organization
  1. ESG Data/Environmental Data
302-4 Reduction of energy consumption
  1. Realization of a Decarbonized Society
GRI 303: Water and Effluents 2018
303-1 Interactions with water as a shared resource
  1. Realization of a Water Recycling-oriented Society
303-2 Management of water discharge-related impacts
  1. Realization of a Water Recycling-oriented Society
  1. Biodiversity
303-3 Water withdrawal
  1. Realization of a Water Recycling-oriented Society
303-4 Water discharge
  1. Realization of a Water Recycling-oriented Society
303-5 Water consumption Water consumption for our company can be calculated as follows: Amount of water intake - Amount of wastewater = Amount of water consumption.
GRI 304: Biodiversity 2016
304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas We do not conduct business activities in areas with high biodiversity value or adjacent areas.
304-2 Significant impacts of activities, products, and services on biodiversity
  1. Biodiversity
304-3 Habitats protected or restored
  1. Biodiversity
GRI 305: Emissions 2016
305-1 Direct (Scope 1) GHG emissions
  1. ESG Data/Environmental Data
  1. Realization of a Decarbonized Society
305-2 Energy indirect (Scope 2) GHG emissions
  1. ESG Data/Environmental Data
  1. Realization of a Decarbonized Society
305-3 Other indirect (Scope 3) GHG emissions
  1. ESG Data/Environmental Data
  1. GHG Emissions in the Supply Chain (Scope 3)
305-5 Reduction of GHG emissions
  1. Realization of a Decarbonized Society
305-6 Emissions of ozone-depleting substances (ODS)
  1. ESG Data/Environmental Data
305-7 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions
  1. ESG Data/Environmental Data
GRI 306: Waste 2020
306-2 Management of significant wasterelated impacts
  1. Realization of a Resource Recycling Society
306-3 Waste generated
  1. ESG Data/Environmental Data
  1. Realization of a Resource Recycling Society
306-4 Waste diverted from disposal
  1. ESG Data/Environmental Data
  1. Realization of a Resource Recycling Society
306-5 Waste directed to disposal
  1. ESG Data/Environmental Data
  1. Realization of a Resource Recycling Society
GRI 308: Supplier Environmental Assessment 2016
308-2 Negative environmental impacts in the supply chain and actions taken
  1. Supply Chain Management
Social topics
Disclosure Number Description References/Response
GRI 401: Employment 2016
401-1 New employee hires and employee turnover
  1. ESG Data/Social Data
401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees
  1. Promoting the Creation of an Employee-friendly Working Environment
401-3 Parental leave
  1. ESG Data/Social Data
GRI 403: Occupational Health and Safety 2018
403-1 Occupational health and safety management system
  1. Promoting the Creation of an Employee-friendly Working Environment (Safety and Health)
  1. EHS Management
403-2 Hazard identification, risk assessment, and incident investigation
  1. Promoting the Creation of an Employee-friendly Working Environment (Safety and Health)
  1. EHS Management
403-3 Occupational health services
  1. Promoting the Creation of an Employee-friendly Working Environment (Safety and Health)
  1. EHS Management
403-4 Worker participation, consultation, and communication on occupational health and safety
  1. Promoting the Creation of an Employee-friendly Working Environment (Safety and Health)
  1. EHS Management
403-6 Promotion of worker health
  1. Organizational Structure to Promote Health Management
403-8 Workers covered by an occupational health and safety management system
  1. EHS Management
403-9 Work-related injuries
  1. ESG Data/Social Data
403-10 Work-related ill health
  1. ESG Data/Social Data
GRI 404: Training and Education 2016
404-1 Average hours of training per year per employee
  1. ESG Data/Social Data
404-2 Programs for upgrading employee skills and transition assistance programs
  1. Expansion of Human Capital (Talent Development)
404-3 Percentage of employees receiving regular performance and career development reviews
  1. Promoting the Creation of an Employee-friendly Working Environment
    All employees have semi-annual goal-setting and evaluation feedback interviews.Implementation rate (Male: 100%, female: 100%)
GRI 405: Diversity and Equal Opportunity 2016
405-1 Diversity of governance bodies and employees
  1. ESG Data/Social Data
  1. ESG Data/Governance Data
  1. Expansion of Human Capital (DE&I)
405-2 Ratio of basic salary and remuneration of women to men
  1. ESG Data/Social Data
GRI 406: Non-discrimination 2016
406-1 Incidents of discrimination and corrective actions taken
  1. ESG Data/Governance Data
GRI 407: Freedom of Association and Collective Bargaining 2016
407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk
  1. Respect for Human Rights
  1. Supply Chain Management
GRI 408: Child Labor 2016
408-1 Operations and suppliers at significant risk for incidents of child labor
  1. Respect for Human Rights
  1. Supply Chain Management
GRI 409: Forced or Compulsory Labor 2016
409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor
  1. Respect for Human Rights
  1. Supply Chain Management
GRI 413: Local Communities 2016
413-1 Operations with local community engagement, impact assessments, and development programs
  1. Biodiversity
GRI 413: Supplier Social Assessment 2016
414-2 Negative social impacts in the supply chain and actions taken
  1. Supply Chain Management
GRI 416: Customer Health and Safety 2016
416-1 Assessment of the health and safety impacts of product and service categories
  1. Manufacturing
  1. Safety and Quality Assurance
GRI 417: Marketing and Labeling 2016
417-1 Requirements for product and service information and labeling
  1. Realization of a Resource Recycling Society (Initiatives)
417-3 Incidents of non-compliance concerning marketing communications
  1. Material Issues and KPI / Thorough Compliance
GRI 418: Customer Privacy 2016
418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data
  1. ESG Data/Governance Data
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system